Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Emerging Therapies For The Treatment Of Patients With Vestibular Schwannomas

Publication Date: February 1, 2018

Last Updated: March 14, 2022

Recommendations

MEDICAL THERAPY

It is recommended that bevacizumab be administered in order to radiographically reduce the size or prolong tumor stability in patients with neurofibromatosis type 2 (NF2) without surgical options. (Level III)

Emerging Therapies For The Treatment Of Patients With Vestibular Schwannomas

Recommendations

MEDICAL THERAPY

Overview

Title

Authoring Organization